Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin
Publication: Annals of Internal Medicine
Volume 109, Number 10
Abstract
Study Objective: To assess the efficacy of the combination of the antiviral agent ganciclovir (9-1,3 dihydroxy-2-propoxymethylguanine) and high-dose intravenous immune globulin for treating cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation.
Design: Nonrandomized prospective trial of combined treatment with two drugs; findings in these patients were compared with those in control patients treated with either of the two drugs alone.
Setting: Medical, pediatric, and intensive care units of a tertiary-care cancer treatment center.
Patients: Consecutive cases of 10 patients in the study group and of 11 patients in a historical control group with evidence of cytomegalovirus pneumonia after bone marrow transplantation for treatment of leukemia or congenital immune deficiency.
Interventions: Study Group (10 patients): ganciclovir, 2. 5 mg/kg body weight, three times daily for 20 days, plus intravenous immune globulin, 500 mg/kg every other day for ten doses. Patients were then given ganciclovir, 5 mg/kg · d three to five times a week for 20 more doses, and intravenous immune globulin, 500 mg/kg twice a week for 8 more doses. Control Group (11 patients): ganciclovir alone (2 patients), 5 mg/kg twice a day for 14 to 21 days; cytomegalovirus hyperimmune globulin (5 patients), 400 mg/kg · d for 10 days; and intravenous immune globulin (4 patients), 400 mg/kg · d for 10 days.
Measurements and Main Results: Responses were observed in all patients treated with combination therapy; 7 of 10 patients were alive and well, and had no recurrence of disease at a median of 10 months after therapy. No therapeutic benefit was observed, and none of the 11 patients treated with either ganciclovir or intravenous immune globulin alone survived (P = 0.001 by Fisher exact test).
Conclusions: Ganciclovir, when combined with high-dose intravenous immune globulin, appears to have significantly altered the outcome of patients with cytomegalovirus pneumonia after allogeneic bone marrow transplantation.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Hirsch M. Herpes group virus infections in the compromised host. In: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host. New York: Plenum Medical Book Co. ; 1981:389-415.
2.
Neiman P, Reeves W, and Ray G. A prospective analysis of interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. J Infect Dis. 1977;136:754-67.
3.
Drew W, Conant M, and Mines R. Cytomegalovirus and Kaposi's sarcoma in young homosexual men. Lancet. 1982;2:125-7.
4.
Wade J, Hintz M, McGuffin R, Springmeyer S, Connor J, and Meyers J. Treatment of Cytomegalovirus pneumonia with high dose acyclovir. Am J Med. 1982;73:249-56.
5.
Meyers J, McGuffin R, Neiman P, Singer J, and Thomas E. Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J Infect Dis. 1980;141:555-62.
6.
O'Reilly R, Reich L, Gold J, and Condie R. A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus infections following marrow transplantation: preliminary results. Transplant Proc. 1983;15:1405-11.
7.
Bowden R, Sayers M, and Fluornoy N. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314:1006-10.
8.
Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies. N Engl J Med. 1986;314:801-5.
9.
Shepp D, Dandliker P, and de Miranda P. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxy methyl] guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985;103:368-73.
10.
Reed E, Dandliker P, and Meyers J. Treatment of cytomegalovirus pneumonia with 9-[2-hydroxy-1-(hydroxy methyl) ethoxymethyl] guanine and high-dose corticosteroids. Ann Intern Med. 1986;105:214-5.
11.
Reed E, Bowden R, Dandliker P, Gleaves C, and Meyers J. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis. 1987;156:641-5.
12.
Bratanow N, Ash R, Turner P, Chitambas C, Hansen R, and Casper J. Successful treatment of serious cytomegalovirus disease with 9(1,3dihydroxy-2-propoxymethyl) guanine in bone marrow transplant patients. Blood. 1986;68(Suppl 1): 280a.
13.
Reisner Y, Kapoor N, and Kirkpatrick D. Transplantation for acute leukemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet. 1981;2:327-31.
14.
Emanuel D, Peppard J, Stover D, Gold J, Armstrong D, and Hammerling U. Rapid immunodiagnosis of cytomegalovirus pneumonia by bronchoalveolar lavage using human and murine monoclonal anti-bodies. Ann Intern Med. 1986;104:476-81.
15.
Gleaves C, Smith T, Shuster E, and Pearson G. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol. 1985;21:217-21.
16.
Chehimi J, Peppard J, and Emanuel D. Selection of an intravenous immune globulin for the immunoprophylaxis of cytomegalovirus infections: an in-vitro comparison of currently available and previously effective immune globulins. Bone Marrow Transplant. 1987;2:395-402.
17.
Emanuel D, Peppard J, Chehimi J, Hammerling U, and O'Reilly R. The diagnostic, prophylactic and therapeutic uses of monoclonal anti-bodies to human cytomegalovirus. Transplant Proc. 1987;19 (Suppl 6):132-7.
18.
Wilson E, Medearis D, Hansen L, and Rubin R. 9-(1-3-dihydroxy-2-propoxymethyl)guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother. 1987;31:1017-20.
19.
Reed E, Bowden R, Dandliker P, and Meyers J. Treatment of cytomegalovirus pneumonia in bone marrow transplant patients with ganciclovir and CMV immunoglobulin. Blood. 1987;70 (Suppl 1):313a.
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 109 • Number 10 • 15 November 1988
Pages: 777 - 782
History
Published in issue: 15 November 1988
Published online: 1 December 2008
Keywords
- Allergy and immunology
- Biochemistry
- Cancer treatment
- Clinical immunology
- Drug research and development
- Drugs
- Globulins
- Health care
- Health care facilities
- Hematology and oncology
- Hospital medicine
- Hospitals
- Immunology
- Infectious diseases
- Intensive care units
- Interstitial lung diseases
- Pharmacology
- Pneumonia
- Prevention, policy, and public health
- Proteins
- Pulmonary diseases
- Research and reporting methods
- Surgery
- Transplantation
Copyright
©1988 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin. Ann Intern Med.1988;109:777-782. doi:10.7326/0003-4819-109-10-777
Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin. Ann Intern Med.1988;109:777-782. doi:10.7326/0003-4819-109-10-777
View More
Get Access
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.